Literature DB >> 7092918

Reversible inhibition of acetylcholinesterase by eseroline, an opioid agonist structurally related to physostigmine (eserine) and morphine.

A Galli, G Renzi, E Grazzini, R Bartolini, P Aiello-Malmberg, A Bartolini.   

Abstract

The action of eseroline--(3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indo l-5-ol--salicylate was tested on preparations of ChE from different sources and on the longitudinal muscle of guinea-pig ileum. While eseroline is eseroline is extremely weak-acting on horse serum BuChE (Ki = 208 +/- 42 microM), it is a rather strong competitive inhibitor of AChE's, its Ki being 0.15 +/- 0.08 microM, 0.22 +/- 0.10 microM and 0.61 +/- 0.12 microM in electric eel, human RBC and rat brain, respectively. Eseroline inhibitory action in AChE in independent of the duration of pre-incubation and appears fully developed in less than 15 sec. This action is also rapidly reversible; after pre-incubation followed by dilution, maximum enzymic activity is regained within 15 sec. The electrically-evoked contractions of the longitudinal strip were inhibited by concentrations of eseroline in the range 0.2-15 microM, while they were increased by concentrations over 20 microM. In the same preparation, without electrical stimulation, but in the presence of naloxone, eseroline induced contractions at concentrations higher than 5 microM. This effect was antagonized by atropine. The inhibitory activity of eseroline parallels, as regards selectivity, potency and kinetics, that of the phenolic anticurare agent edrophonium, while it differs markedly from that of physostigmine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7092918     DOI: 10.1016/0006-2952(82)90009-0

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  Studies on new, centrally active and reversible acetylcholinesterase inhibitors.

Authors:  F Arnal; L J Coté; S Ginsburg; G D Lawrence; A Naini; M Sano
Journal:  Neurochem Res       Date:  1990-06       Impact factor: 3.996

Review 2.  Cholinergic modulation by opioid receptor ligands: potential application to Alzheimer's disease.

Authors:  William C Motel; Andrew Coop; Christopher W Cunningham
Journal:  Mini Rev Med Chem       Date:  2013-03       Impact factor: 3.862

3.  Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group.

Authors:  Cecilia Bartolucci; Jure Stojan; Qian-sheng Yu; Nigel H Greig; Doriano Lamba
Journal:  Biochem J       Date:  2012-06-01       Impact factor: 3.857

4.  Analgesic and antineuropathic drugs acting through central cholinergic mechanisms.

Authors:  Alessandro Bartolini; Lorenzo Di Cesare Mannelli; Carla Ghelardini
Journal:  Recent Pat CNS Drug Discov       Date:  2011-05-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.